Candidate for a live vaccine?

Immune dysfunction is a well-known phenomenon in end-stage liver disease (ESLD). The pretransplant period offers a unique window for primary care physicians to optimize the transplant's vaccine protection before antirejection medications are initiated. Live vaccinations are selected cautiously...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbatemarco, Justin Ralph, Taege, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749104/
https://www.ncbi.nlm.nih.gov/pubmed/29302565
http://dx.doi.org/10.4103/jfmpc.jfmpc_67_17
_version_ 1783289532393717760
author Abbatemarco, Justin Ralph
Taege, Alan
author_facet Abbatemarco, Justin Ralph
Taege, Alan
author_sort Abbatemarco, Justin Ralph
collection PubMed
description Immune dysfunction is a well-known phenomenon in end-stage liver disease (ESLD). The pretransplant period offers a unique window for primary care physicians to optimize the transplant's vaccine protection before antirejection medications are initiated. Live vaccinations are selected cautiously but the varicella-zoster virus (VZV) vaccine, Zostavax, is recommended for pretransplant candidates. This case highlights an ESLD patient who developed disseminated cutaneous VZV within 30 days of vaccination.
format Online
Article
Text
id pubmed-5749104
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-57491042018-01-04 Candidate for a live vaccine? Abbatemarco, Justin Ralph Taege, Alan J Family Med Prim Care Case Report Immune dysfunction is a well-known phenomenon in end-stage liver disease (ESLD). The pretransplant period offers a unique window for primary care physicians to optimize the transplant's vaccine protection before antirejection medications are initiated. Live vaccinations are selected cautiously but the varicella-zoster virus (VZV) vaccine, Zostavax, is recommended for pretransplant candidates. This case highlights an ESLD patient who developed disseminated cutaneous VZV within 30 days of vaccination. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5749104/ /pubmed/29302565 http://dx.doi.org/10.4103/jfmpc.jfmpc_67_17 Text en Copyright: © 2017 Journal of Family Medicine and Primary Care http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Case Report
Abbatemarco, Justin Ralph
Taege, Alan
Candidate for a live vaccine?
title Candidate for a live vaccine?
title_full Candidate for a live vaccine?
title_fullStr Candidate for a live vaccine?
title_full_unstemmed Candidate for a live vaccine?
title_short Candidate for a live vaccine?
title_sort candidate for a live vaccine?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749104/
https://www.ncbi.nlm.nih.gov/pubmed/29302565
http://dx.doi.org/10.4103/jfmpc.jfmpc_67_17
work_keys_str_mv AT abbatemarcojustinralph candidateforalivevaccine
AT taegealan candidateforalivevaccine

Ejemplares similares